International Stem Cell (ISCO) versus Its Rivals Head to Head Review

International Stem Cell (OTCMKTS: ISCO) is one of 528 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare International Stem Cell to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.

Institutional & Insider Ownership

45.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 83.2% of International Stem Cell shares are owned by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk & Volatility

International Stem Cell has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, International Stem Cell’s competitors have a beta of 1.17, suggesting that their average stock price is 17% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for International Stem Cell and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
International Stem Cell 0 0 0 0 N/A
International Stem Cell Competitors 3823 11145 25285 846 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 66.08%. Given International Stem Cell’s competitors higher possible upside, analysts plainly believe International Stem Cell has less favorable growth aspects than its competitors.


This table compares International Stem Cell and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
International Stem Cell -23.26% -123.16% -31.68%
International Stem Cell Competitors -1,825.44% -92.49% -26.19%

Valuation and Earnings

This table compares International Stem Cell and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
International Stem Cell $7.46 million -$6.06 million -1.14
International Stem Cell Competitors $2.03 billion $140.19 million -1.81

International Stem Cell’s competitors have higher revenue and earnings than International Stem Cell. International Stem Cell is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


International Stem Cell competitors beat International Stem Cell on 7 of the 10 factors compared.

About International Stem Cell

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with's FREE daily email newsletter.

Leave a Reply